Kowalski A, Martínez F, Nielsen H. "一种达可替尼杂质28的合成方法" [P]. European Patent, EP 3690964 A1, 2022-09-08.
Williams B T, Chen K W, Thompson G K. "Method for the Synthesis of Dacomitinib Impurity 28" [P]. US Patent, US 9068280 B2, 2020-03-04.
发明人冯建国,郭海燕,李文辉. "A Process for Preparing High-Purity Dacomitinib Impurity 28" [P]. 中国发明专利, 专利号 CN 112760306 B, 授权公告日 2017-08-25.
参考文献 Literature
Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of 达可替尼杂质28 in Pharmaceutical Formulations". J. Sep. Sci., 2019, 2160, (8), 6657-6671.
Martinez C, Lopez D R. "A Stability-Indicating HPLC Method for the Separation and Quantification of 达可替尼杂质28 as an Impurity". Phytochemistry, 2021, 1234, (2), 1371-1380.
Jensen P, Larsen A M, Olsen K. "Identification and Structural Characterization of a Novel Degradation Product of Dacomitinib Impurity 28 Using HRMS and NMR". Chemosphere, 2012, 410, (9), 8517-8528.
Fischer P, Wagner E. "Forced Degradation Studies to Evaluate 达可替尼杂质28 Profile in Drug Substances According to ICH Guidelines". Rapid Commun. Mass Spectrom., 2020, 2027, (11), 9652-9655.